SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use.
D000818:Animals; D002277:Carcinoma / Q000532:radiotherapy; D002460:Cell Line; D002490:Central Nervous System / Q000187:drug effects; D006224:Cricetinae; D004285:Dogs; D017341:Etanidazole; D005260:Female; D066298:In Vitro Techniques; D050356:Lipid Metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008920:Misonidazole / Q000494:pharmacology; D009374:Neoplasms, Experimental / Q000532:radiotherapy; D009593:Nitroimidazoles / Q000494:pharmacology*; D011838:Radiation-Sensitizing Agents; D012513:Sarcoma, Experimental / Q000532:radiotherapy; D014965:X-Rays
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D017341:Etanidazole; C027710:SR 2555; D008920:Misonidazole